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Abstract 
Background: Although more than one‑third of the patients with acute heart failure (AHF) have diabetes mellitus 
(DM), it is unclear if DM has an adverse impact on clinical outcomes. This study compared the outcomes in patients 
hospitalized for AHF stratified by DM and left ventricular ejection fraction (LVEF).
Methods: The Korean Acute Heart Failure registry prospectively enrolled and followed 5625 patients from March 
2011 to February 2019. The primary endpoints were in‑hospital and overall all‑cause mortality. We evaluated the 
impact of DM on these endpoints according to HF subtypes and glycemic control.
Results: During a median follow‑up of 3.5 years, there were 235 (4.4%) in‑hospital mortalities and 2500 (46.3%) 
overall mortalities. DM was significantly associated with increased overall mortality after adjusting for potential con‑
founders (adjusted hazard ratio [HR] 1.11, 95% confidence interval [CI] 1.03–1.22). In the subgroup analysis, DM was 
associated with higher a risk of overall mortality in heart failure with reduced ejection fraction (HFrEF) only (adjusted 
HR 1.14, 95% CI 1.02–1.27). Inadequate glycemic control (HbA1c ≥ 7.0% within 1 year after discharge) was significantly 
associated with a higher risk of overall mortality compared with adequate glycemic control (HbA1c < 7.0%) (44.0% vs. 
36.8%, log‑rank p = 0.016).
Conclusions: DM is associated with a higher risk of overall mortality in AHF, especially HFrEF. Well‑controlled diabetes 
(HbA1c < 7.0%) is associated with a lower risk of overall mortality compared to uncontrolled diabetes.
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Background
Around 26 million people suffer from heart failure 
(HF) globally, and the prevalence is increasing with 
an increasing longevity, prevalence of risk factors, and 
improved survival in patients with cardiovascular dis-
eases [1, 2]. In the United States, HF is the primary 
cause of hospitalization among patients aged > 65 years 
[3]. Hospitalization for HF is associated with a high 
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75% patients with HF have ≥ 1 comorbidity, and these 
comorbidities make overall clinical outcomes worse [6]. 
In a recent meta-analysis, patients with diabetes mel-
litus (DM) were suggested to have a two-fold increase 
in the risk of HF [7]. DM is present in ~ 35% patients 
hospitalized with acute HF [8]. Multiple factors such as 
ischemia, hypertension, and extracellular fluid volume 
expansion are involved in the pathogenesis of HF in 
DM [9, 10]. While DM is associated with an increased 
cardiovascular morbidity and mortality in patients 
with chronic HF with reduced left ventricular ejection 
fraction (HFrEF) [11, 12], its independent impact on 
in-hospital and long-term outcomes after HF hospitali-
zation is unclear. Data from some large registries and 
clinical trials suggest that DM is associated with worse 
in-hospital and post-discharge outcomes in patients 
with acute HF [13–18]. Other studies do not suggest a 
significant association of DM with mortality in patients 
hospitalized for HF after adjusting for confounding fac-
tors [19–22]. Thus, the independent association of DM 
with mortality in patients with HF remains unknown. It 
is also unclear if DM has similar adverse impact across 
HF subtypes such as HFrEF, HF with preserved ejection 
fraction (HFpEF), or HF with mid-range ejection frac-
tion (HFmrEF).
We compared acute HF-associated in-hospital and 
overall all-cause mortality in patients with and with-
out DM using the Korean Acute Heart Failure Regis-




We evaluated the patients with acute HF enrolled 
in the KorAHF registry (ClinicalTrial.gov identifier, 
NCT01389843) [23]. Briefly, the KorAHF registry is a 
prospective multicenter cohort study of 5625 patients 
admitted for acute heart failure (AHF) in 10 tertiary uni-
versity hospitals between March 2011 and February 2014 
who have been followed for > 5 years until February 2019. 
Patients who had signs or symptoms of HF and met ≥ 1 
of the following criteria were enrolled in this registry: 
(1) lung congestion or (2) objective evidence of left ven-
tricular (LV) systolic dysfunction or (3) structural heart 
disease.
We excluded 210 patients where there was no informa-
tion on LV ejection fraction (LVEF) and 21 patients who 
were lost to follow-up. Finally, 5394 patients with AHF 
and known DM status and LVEF were enrolled for analy-
ses (Fig. 1).
Data collection and outcome definition
Data were collected at each hospital and entered into a 
web-based Clinical Research and Trial (iCReaT) sys-
tem case-report form of the Korea National Institute of 
Health. Detailed information was collected at the time of 
admission, and follow-up data were collected from the 
patients by the attending physician at 30 days and 3, 6, 12, 
24, 36, 48, and 60 months after discharge. Data on patient 
demographics, medical history, physical signs, labora-
tory test results, electrocardiography, echocardiography, 
medications, and outcomes were collected. The mortality 
Fig. 1 Flow chart of the study. KorAHF registry, Korean Acute Heart Failure registry
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data for patients lost to follow-up was collected from the 
National Insurance data or National Death Records.
Definition of DM and glycemic control
DM was defined as self-reported, history of anti-hyper-
glycemic agent use, or newly diagnosed during hospi-
talization [17]. Newly diagnosed DM was defined as a 
glycated hemoglobin (HbA1c) ≥ 6.5% when measured 
after a random glucose level ≥ 200  mg/dl at enrollment. 
We additionally classified DM patients based on HbA1c 
levels measured at the follow-up visit ≤ 1 year from dis-
charge. We defined well-controlled and uncontrolled 
DM by an HbA1c < 7.0% and ≥ 7.0% at the follow-up 
visit, respectively. According to LVEF, we categorized 
patients with AHF into 3 groups: LVEF < 40% (HFrEF), 
40% ≤ LVEF < 50% (HFmrEF), and LVEF ≥ 50% (HFpEF).
Statistical analysis
Baseline characteristics as per DM status were compared 
using the χ2 test for categorical variables and the unpaired 
Student’s t-test for continuous variables. Kaplan–Meier 
survival curves as per DM status were compared using 
the log-rank test. We used the multivariable Cox pro-
portional hazard regression model to evaluate the asso-
ciation between DM and mortality in patients with AHF. 
Potential confounders which were different at baseline 
in patients with and without DM, or were considered 
clinically significant including age, sex, body mass index 
(BMI), etiology of HF (ischemic or non-ischemic), prior 
admission for HF, use of parenteral inotropic agents, 
serum creatinine concentration (< 2.0 or ≥ 2.0  mg/dL), 
elevated brain natriuretic peptides (BNP) (≥ 500  pg/
mL) or N-terminal pro-brain natriuretic peptides (NT-
proBNP) (≥ 1000  pg/mL), New York Heart Association 
(NYHA) class (III–IV or I–II) on admission, and smok-
ing status (current or ex-smoker vs. never-smoker) were 
adjusted for in the multivariable model. An interaction 
between DM and potential confounders was assessed by 
adding interaction terms in the Cox proportional hazard 
regression model. All p-values were two-sided, and p-val-
ues < 0.05 were considered statistically significant. Statis-
tical analyses were performed using SAS software version 
9.4 (SAS Institute Inc., Cary, NC, USA) and R version 
3.6.0 with packages (“survival”, and “survminer”).
Results
Baseline characteristics
In the study population, 2321 patients with AHF had 
DM (43.0%) (Table  1). Patients with DM had a higher 
prevalence of risk factors like old age, obesity, hyper-
tension, ischemic heart disease, chronic kidney disease, 
and cerebrovascular disease. Patients with DM had a 
higher proportion of patients with a BNP ≥ 500 pg/mL or 
NT-proBNP ≥ 1000 pg/mL, NYHA class III-IV on admis-
sion, acute pulmonary edema on chest X-ray, a higher 
level of systolic blood pressure, C-reactive protein, serum 
potassium and creatinine concentration, and lower 
serum sodium concentration and LVEF compared to 
those without DM. Besides, patients with DM were more 
likely to be on parenteral diuretics, inotropic agents, and 
vasodilators. However, aldosterone antagonists were pre-
scribed less frequently in patients with DM.
All patients underwent echocardiography during their 
index admission (Table 1). There were no significant dif-
ferences in the LV end-diastolic dimension (LVEDD) 
and LV end-systolic dimension (LVESD) between the 
two groups. However, there was a significant difference 
in the LVEF (38.5 ± 15.9% vs. 36.7 ± 15.0%, p < 0.001). 
Furthermore, LV diastolic function parameters such as 
E/e′ (20.1 ± 10.8 vs. 22.7 ± 12.2, p < 0.001) and right ven-
tricular (RV) systolic pressure (43.2 ± 14.9  mmHg vs. 
44.9 ± 15.4 mmHg, p < 0.001) were worse in patients with 
DM. Conversely, patients without DM had a larger LA 
volume index (66.7 ± 41.9 mL/m2 vs. 59.6 ± 42.0 mL/m2, 
p < 0.001).
In‑hospital and overall mortality as per DM status
During a median follow-up of 3.5 years, there were 235 
(4.4%) deaths during the index hospitalization, and 2500 
(46.3%) deaths during the overall follow-up period. 
Patients with DM had a higher incidence of in-hospital 
mortality and overall mortality compared to patients 
without DM (Fig.  2). After adjusting for potential con-
founders including age, sex, BMI, etiology of heart fail-
ure (ischemic vs. non-ischemic), prior admission for HF, 
parenteral inotropic use, serum creatinine concentration, 
elevated BNP/NT-proBNP, NYHA class III-IV on admis-
sion, and smoking status, DM was still independently 
associated with overall mortality (adjusted hazard rate 
[HR] 1.11, 95% confidence interval [CI] 1.03–1.22).
Independent predictors of in‑hospital and overall mortality
Results of multivariable Cox proportional hazard regres-
sion for in-hospital and overall all-cause mortality are 
reported in Table  2. DM was not independently associ-
ated with an increased in-hospital mortality (HR 0.81, 
95% CI 0.61–1.07, p = 0.137). Use of parenteral inotropes, 
age, ischemic etiology, and a higher serum creatinine 
concentration also independently predicted in-hospital 
mortality.
DM was an independent predictor for overall mortality 
(HR 1.11, 95% CI 1.03–1.22, p = 0.013). Other variables, 
such as old age, male sex, higher BMI, ischemic etiology, 
acute decompensated HF, use of parenteral inotropes, 
high concentrations of serum creatinine and BNP/NT-
proBNP during index hospitalization, and NYHA class 
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Table 1 Baseline clinical characteristics according to diabetes mellitus (DM)
Values are presented as mean ± standard deviation, or n (%)
DM diabetes mellitus, SBP systolic blood pressure, DBP diastolic blood pressure, BNP brain natriuretic peptides, NT-proBNP N-terminal pro-brain natriuretic peptides, 
hsCRP high sensitivity C-reactive protein, CRP C-reactive protein, BUN blood urea nitrogen, LVEDD left ventricular end-diastolic dimension, LVEDV left ventricular end-
diastolic volume, LVEF left ventricular ejection fraction, LA left atrium, RVSP right ventricular systolic pressure, ACEIs angiotensin converting enzyme inhibitors, ARBs 
angiotensin receptor blockers, AAs aldosterone antagonists
Variables All patients (N = 5394) Non‑DM (N = 3073) DM (N = 2321) P‑value
Age 68.5 ± 14.5 67.6 ± 15.9 69.6 ± 12.3 < 0.001
Body mass index (kg/m2) 23.0 ± 3.9 23.0 ± 3.9 23.7 ± 3.8 < 0.001
Male, N (%) 2872 (53.2) 1596 (51.9) 1277 (55.0) 0.023
Current smoker, N (%) 961 (17.8) 546 (17.8) 415 (17.9) 0.086
Risk factors, N (%)
 Hypertension 3183 (59.0) 1554 (50.6) 1629 (70.2) < 0.001
 Ischemic heart disease 1501 (27.8) 636 (20.7) 865 (37.2) < 0.001
 Atrial fibrillation 1523 (28.2) 921 (30.0) 602 (25.9) 0.001
 Chronic lung disease 608 (11.3) 350 (11.4) 258 (11.1) 0.492
 Chronic kidney disease 756 (14.0) 277 (9.0) 479 (20.6) < 0.001
 Cerebrovascular disease 807 (15.0) 405 (13.2) 402 (17.3) < 0.001
 Previous heart failure 2539 (47.1) 1380 (44.9) 1159 (49.9) < 0.001
Physical and laboratory findings
 SBP, mmHg 131.4 ± 30.1 130.4 ± 29.4 132.8 ± 30.9 0.003
 DBP, mmHg 78.7 ± 18.7 79.2 ± 18.8 78.1 ± 18.6 0.028
 Heart rate, beats/min 92.8 ± 25.9 92.5 ± 26.4 93.1 ± 25.2 0.379
 Glucose, mg/dL 155.3 ± 76.7 129.6 ± 47.8 189.1 ± 94.1 < 0.001
 Total cholesterol, mg/dL 151.8 ± 43.2 153.9 ± 42.2 149.2 ± 44.4 < 0.001
 BNP ≥ 500 pg/mL or NT‑proBNP ≥ 1000 pg/mL 4047 (75.0) 2267 (73.8) 1780 (76.7) 0.014
 CRP, mg/dL 2.4 ± 4.3 2.1 ± 3.5 2.9 ± 5.0 < 0.001
 hsCRP, mg/dL 2.3 ± 4.2 2.0 ± 3.8 2.6 ± 4.6 < 0.001
 Sodium, mmol/L 137.5 ± 4.8 138.0 ± 4.6 136.8 ± 5.0 < 0.001
 Potassium, mmol/L 4.4 ± 0.7 4.3 ± 0.6 4.5 ± 0.8 < 0.001
 BUN, mg/dL 26.1 ± 16.3 23.7 ± 14.3 29.2 ± 18.3 < 0.001
 Creatinine, mg/dL 1.5 ± 1.5 1.3 ± 1.3 1.7 ± 1.6 < 0.001
 NYHA class III‑IV, N (%) 4582 (84.9) 2558 (83.2) 2024 (87.2) < 0.001
 Acute pulmonary edema on chest X‑ray, N (%) 1039 (19.3) 502 (16.3) 537 (23.1) < 0.001
Echocardiographic findings
 LVEDD, mm 57.4 ± 10.1 57.5 ± 10.6 57.4 ± 9.3 0.863
 LVESD, mm 45.2 ± 12.3 45.1 ± 12.8 45.4 ± 11.7 0.302
 LVEF (%) 37.8 ± 15.6 38.5 ± 15.9 36.7 ± 15.0 < 0.001
 LA volume index, mL/m2 63.8 ± 42.1 66.7 ± 41.9 59.6 ± 42.0 < 0.001
 E′, cm/s 5.0 ± 2.3 5.2 ± 2.1 4.8 ± 2.5 < 0.001
 S′, cm/s 5.1 ± 2.0 5.1 ± 2.1 5.0 ± 1.9 0.026
 E/E′ 21.2 ± 11.5 20.1 ± 10.8 22.7 ± 12.2 < 0.001
 RVSP 43.9 ± 15.1 43.2 ± 14.9 44.9 ± 15.4 < 0.001
Management, N (%)
 Parenteral diuretics 4062 (75.3) 2222 (72.3) 1840 (79.3) < 0.001
 Parenteral inotropics 1672 (31.0) 760 (24.7) 912 (39.3) < 0.001
 Parenteral vasodilators 2231 (41.4) 1105 (36.0) 1126 (48.5) < 0.001
 ACEIs/ARBs at admission 3383 (62.7) 1977 (64.3) 1406 (60.6) 0.001
 ACEIs/ARBs at discharge 3601 (66.8) 2117 (68.9) 1484 (63.9) < 0.001
 Beta‑blockers at admission 2054 (38.1) 1183 (38.5) 871 (37.5) 0.001
 Beta‑blockers at discharge 2725 (50.5) 1533 (49.9) 1192 (51.4) 0.285
 AAs at admission 2206 (40.9) 1379 (44.9) 827 (35.6) < 0.001
 AAs at discharge 2443 (45.3) 1472 (47.9) 971 (41.8) < 0.001
 Warfarin at discharge 1531 (28.4) 965 (31.4) 566 (24.4) < 0.001
 Heart transplantation 69 (1.3) 13 (0.4) 56 (2.4) < 0.001
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III-IV on admission also independently predicted higher 
overall mortality.
In‑hospital and overall mortality according to DM 
in subgroup by LVEF
Patients with DM had a higher in-hospital mortality rate 
vs. patients without DM in all LVEF subgroups (HFrEF 
7.1% vs. 3.4%, HFmrEF 4.3% vs. 3.2%, HFpEF 3.8% vs. 
2.7%). However, there was no significant association of 
DM with higher in-hospital mortality rate after adjust-
ing for potential confounders (HFrEF, adjusted HR 0.96, 
95% CI 0.68–1.35, HFmrEF, adjusted HR 0.71, 95% CI 
0.33–1.53, HFpEF, adjusted HR 0.79, 95% CI 0.41–1.51) 
(Table 3).
DM had differential impact on overall mortality as per 
the HF subtype. In HFrEF, DM was significantly associ-
ated with an increased risk of overall mortality after 
adjusting for potential confounders (adjusted HR 1.14, 
95% CI 1.02–1.27). However, DM was not significantly 
associated with overall mortality in patients with HFm-
rEF (adjusted HR 0.99, 95% CI 0.80–1.22) and HFpEF 
(adjusted HR 1.13, 95% CI 0.96–1.34) (Table  3). The 
Kaplan–Meier analysis also revealed significantly worse 
overall mortality in patients with HFrEF and DM vs. 
HFrEF and no DM (40.2% vs. 52.7%, log-rank p < 0.001) 
(Fig. 3).
Fig. 2 Comparison of in‑hospital and overall all‑cause mortality as 
per DM status
Table 2 Independent predictors of in-hospital and overall 
mortality on  multivariable Cox proportional hazard 
regression model
a Adjusted for age, sex, body mass index, etiology of heart failure (ischemic 
vs. non-ischemic), prior admission history due to HF, parenteral inotropics 
usage, creatinine concentration (< 2.0 vs. ≥ 2.0 mg/dL), elevated BNP (≥ 500) or 
NT-proBNP (≥ 1000), NYHA class (III-IV or I-II) on admission, and smoking status 
(current or ex-smoker vs. never-smoker)
Variables Adjusted  HRa P value
In‑hospital mortality
 DM 0.81 (0.61–1.07) 0.137
 Age (years) 1.03 (1.02–1.04) < 0.001
 Ischemic cause (vs non‑ischemic cause) 1.41 (1.07–1.86) 0.016
 Parenteral inotropics usage 5.14 (3.43–7.68) < 0.001
 Serum creatinine ≥ 2.0 (vs < 2.0 mg/dL) 1.54 (1.15–2.07) 0.015
Overall mortality
 DM 1.11 (1.03–1.22) 0.013
 Age (years) 1.04 (1.04–1.05) < 0.001
 Sex (male) 1.26 (1.14–1.38) < 0.001
Body mass index (kg/m2)
 Underweight vs. Normal 1.66 (1.47–1.88) < 0.001
 Overweight or obese vs. Normal 0.80 (0.73–0.89) < 0.001
Ischemic cause (vs non‑ischemic cause) 1.17 (1.07–1.27) < 0.001
Prior admission history due to HF 1.51 (1.39–1.64) < 0.001
Parenteral inotropics usage 1.41 (1.30–1.55) < 0.001
Serum creatinine ≥ 2.0 (vs < 2.0 mg/dL) 1.63 (1.50–1.83) < 0.001
Higher BNP (≥ 500), or NT‑proBNP (≥ 1000) 
during index hospitalization
1.32 (1.22–1.49) < 0.001
NYHA class III–IV on admission 1.35 (1.22–1.49) < 0.001
Table 3 In-hospital and overall mortality according to DM 
in 3 subtypes of HF
Adjusted for age, sex, body mass index, etiology of heart failure (ischemic 
vs. non-ischemic), prior admission history due to HF, parenteral inotropics 
usage, creatinine concentration (< 2.0 vs. ≥ 2.0 mg/dL), elevated BNP (≥ 500) or 
NTproBNP (≥ 1000), NYHA class (III–IV or I–II) on admission, and smoking status 
(current or ex-smoker vs. never-smoker)
Diabetes mellitus 
(DM)
Unadjusted HR (95% 
CI)
Adjusted HR (95% CI)1
In‑hospital mortality
 LVEF < 40%
  Non‑DM 1.00 1.00
  DM 1.28 (0.92–1.77) 0.96 (0.68–1.35)
 40% ≤ LVEF < 50%
  Non‑DM 1.00 1.00
  DM 0.83 (0.41–1.68) 0.71 (0.33–1.53)
 LVEF ≥ 50%
  Non‑DM 1.00 1.00
  DM 0.94 (0.50–1.77) 0.79 (0.41–1.51)
Overall mortality
 LVEF < 40%
  Non‑DM 1.00 1.00
  DM 1.48 (1.33–1.64) 1.14 (1.02–1.27)
 40% ≤ LVEF < 50%
  Non‑DM 1.00 1.00
  DM 1.19 (0.98–1.44) 0.99 (0.80–1.22)
 LVEF ≥ 50%
  Non‑DM 1.00 1.00
  DM 1.15 (0.98–1.35) 1.13 (0.96–1.34)
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Overall mortality as per the prespecified subgroup 
and glycemic control
Figure 4 shows the association between DM and overall 
mortality in a stratified group as per the potential con-
founders, including age, sex, ischemic etiology, hyperten-
sion, chronic kidney disease, de novo HF, LVEF < 40%, 
and smoking status. The impact of DM on overall mor-
tality was generally consistent across stratified sub-
groups (p-interaction ≥ 0.05). However, there was a 
significant difference in the impact of DM on overall 
mortality between smoker (current or ex-smoker) and 
never-smoker (p for interaction = 0.022).
Figure  5 shows that patients with uncontrolled DM 
(HbA1c ≥ 7.0%) had significantly higher overall mor-
tality compared to patients with well-controlled DM 
(HbA1c < 7.0%) by Kaplan–Meier analysis (44.0% vs. 
36.8%, log-rank p = 0.016).
Discussion
The main findings of our study are as follows: (1) patients 
with AHF and DM have a significantly higher in-hospi-
tal and overall mortality vs. patients with AHF and no 
DM; (2) DM was significantly associated with a higher 
overall mortality even after adjusting for potential con-
founding factors including age, sex, BMI, HF etiology, 
renal function, and HF severity; (3) DM had a significant 
association with higher overall mortality in HFrEF, but 
not HFmrEF and HFpEF; (4) patients with poor glyce-
mic control after discharge (HbA1c ≥ 7.0%) had a higher 
overall mortality vs. patients with adequate glycemic con-
trol (HbA1c < 7.0%).
Previous studies in HF have compared the clinical char-
acteristics and outcomes in patients with and without 
DM. However, there are few reports comparing clinical 
outcomes stratified by DM in HFpEF [12, 24, 25]. Moreo-
ver, there is no data from a large registry or clinical trials 
Fig. 3 Kaplan–Meier curves of all‑cause mortality according to DM in subgroup by LVEF
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in patients with HFmrEF. The CHARM program dem-
onstrated that DM was significantly associated with a 
higher mortality and morbidity in HFrEF and HFpEF [11]. 
Another large-scale study from the I-PRESERVE trial 
(Irbesartan in Heart Failure with Preserved Ejection Frac-
tion) showed that patients with DM had more significant 
structural and functional echocardiographic abnormali-
ties and worse clinical outcomes compared to patients 
without DM in HFpEF [24]. A recent prospective HFpEF 
study showed a significant association of DM with long-
term mortality in women, but not in men [25]. Similar to 
HFrEF, these studies demonstrate a significant associa-
tions of DM with higher mortality in HFpEF. The mecha-
nisms for poor prognosis of HF with DM are unclear.
Some of these mechanisms are: (1) DM causes micro-
angiopathy, myocardial fibrosis, and autonomic neuropa-
thy and these lead to diabetic cardiomyopathy [26]; (2) 
hyperglycemia leads to lipid accumulation in the heart, 
and this can cause cellular damage by lipotoxicity [27]; (3) 
lipid accumulation, collagen deposition and fibrosis, and 
hyperinsulinemia due to insulin resistance increases risk 
of hypertrophy of the heart [28, 29]; (4) DM may promote 
extracellular matrix expansion which is associated with a 
higher mortality in HF [30]; (5) impaired branched-chain 
amino acids catabolism and insulin signaling are asso-
ciated with HF [31]; (6) distinct pathways related to 
inflammation, protein phosphorylation, and neutrophil 
degranulation are associated with DM in HF [32].
Why DM was not associated with an increased mor-
tality in HFpEF and HFmrEF is unclear. The LVEF cut-
off to classify HF in previous studies was different from 
the current updated guidelines for the diagnosis and 
treatment of HF that are accepted and used in clini-
cal practice [33]. The CHARM program did not provide 
detailed echocardiographic data. The I-PRESERVE trial 
used an LVEF cutoff of 45%, and echocardiographic data 
were shown for < 20% of the whole study population. 
Our results require cautious interpretation. In general, 
patients with DM had a higher overall mortality, but this 
association was not statistically significant in HFpEF and 
HFmrEF after adjusting for risk factors such as old age, 
ischemic etiology, and severity of initial presentation.
Patients with HFmrEF have similar clinical character-
istics as patients with HFpEF [34–37]. Recent studies 
demonstrate that mortality rates in HFmrEF are similar 
to those in HFpEF [35–38]. Although there are no studies 
on the association of DM with mortality in patients with 
HFmrEF, our study shows that this association is different 
Fig. 4 Overall all‑cause mortality as per the prespecified subgroup
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from HFrEF and HFpEF. If HFmrEF is a distinct clinical 
syndrome or if these patients are in-transition between 
HFrEF and HFpEF is unknown [39]. Since there were 
limited patients with HFmrEF in our study, this associa-
tion needs to be further explored.
Our study has important implications. First, we ana-
lyzed one of the largest prospective cohorts comparing 
the characteristics and clinical outcomes in patients 
with AHF, with and without DM. Second, our study 
analyzed baseline echocardiographic findings in all 
patients, which is unique and challenging to obtain in 
large HF registries. Third, we evaluated both in-hospi-
tal and overall all-cause mortality. This helped estimate 
both short and long-term impact of DM on mortality 
in patients with AHF. Fourth, we compared mortality in 
3 subtypes of HF based on LVEF. To our best knowl-
edge, this is the first study to evaluate the association 
of DM with mortality in HFrEF, HFmrEF, and HFpEF. 
Since the characteristics and prognosis of patients with 
HFpEF and HFmrEF are unknown, these results may 
help understand the clinical implications of HFpEF and 
HFmrEF. Lastly, we also demonstrate that an adequate 
glycemic control during follow-up was associated with 
an improved long-term prognosis in patients with AHF 
and DM.
Limitations
There are several limitations of our study. First, this is an 
observational study. To evaluate the effect of glycemic 
control, it has intrinsic limitations of non-randomized 
comparisons such as the different distribution of other 
clinical risk factors and the possibility of unmeasured 
confounding factors. Second, our endpoint was only 
all-cause mortality. Detailed clinical outcomes such as 
cardiovascular death and re-hospitalization for HF may 
help better understand the impact of DM on outcomes 
in AHF. Third, many recent studies have evaluated the 
cardiovascular safety of anti-diabetic medications. While 
dipeptidyl peptidase 4 (DPP-4) inhibitors had a neutral 
effect, sodium-glucose co-transporter 2 (SGLT2) inhibi-
tors were most favorable among all classes of anti-dia-
betic medications for reducing the risk of HF [40, 41]. 
However, SGLT2 inhibitors were not prescribed dur-
ing the enrollment period of our registry. Therefore, our 
study could not evaluate their effect on HF.
Conclusions
Our study, using large registry data with echocar-
diographic information from all participants, shows 
that DM is significantly associated with an increased 
risk of overall mortality in AHF, especially HFrEF. 
Fig. 5 Overall all‑cause mortality as per glycemic control after discharge in patients with DM. *Well‑controlled DM as an HbA1c < 7.0% at a 
follow‑up visit within 1 year after discharge; Uncontrolled DM as an HbA1c ≥ 7.0%
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Well-controlled diabetes (HbA1c < 7.0%) was associated 
with a lower risk of overall mortality compared with 
uncontrolled diabetes (HbA1c ≥ 7.0%) in patients with 
AHF and DM.
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